Erotinib is a receptor tyrosine kinase inhibitor (EGFR antagonist), a molecular targeted therapeutic drug that inhibits phosphorylation reactions by competitively binding to the catalytic site of the intracellular region of the receptor tyrosine kinase with adenosine triphosphate, thereby blocking downstream proliferative signal transduction, inhibiting the activity of tumor cell ligand dependent HER-1/EGFR, and achieving the effect of inhibiting tumor cell proliferation.
Manufacturing
